Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_assertion type Assertion NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_head.
- NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_assertion description "[The 5-year survival rates were 57% for esophageal cancer patients with HER2 amplification compared with 32% without, but the difference in overall survival was not significant (P�=�.37).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_provenance.
- NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_assertion evidence source_evidence_literature NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_provenance.
- NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_assertion SIO_000772 21267790 NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_provenance.
- NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_assertion wasDerivedFrom befree-2016 NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_provenance.
- NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_assertion wasGeneratedBy ECO_0000203 NP867817.RAaMpp0GPOIT493RXcXlaUFlHYLkhX8PUAexjcYw46PtA130_provenance.